75 related articles for article (PubMed ID: 15523142)
41. Estimation of bone strength parameters and response to treatment in McCune-Albright syndrome using peripheral quantitative computed tomography of the tibia.
Atsali E; Zoubos AB; Stathopoulos KD; Stefos E; Bournazos I; Papadimitriou A; Nicolaidou P; Skarantavos G
J Clin Densitom; 2012; 15(4):461-466. PubMed ID: 22819140
[No Abstract] [Full Text] [Related]
42. [Proceedings: Polyostatic fibrous dysplasia with vitamin D-resistant rachitis].
Karte H
Monatsschr Kinderheilkd (1902); 1975 May; 123(5):477. PubMed ID: 176578
[No Abstract] [Full Text] [Related]
43. Oral alendronate in pediatric chronic recurrent multifocal osteomyelitis.
Hirano D; Chiba K; Yamada S; Ida H
Pediatr Int; 2017 Apr; 59(4):506-508. PubMed ID: 28401741
[TBL] [Abstract][Full Text] [Related]
44. Idiopathic sporadic tumoral calcinosis of the hip: successful oral bisphosphonate therapy.
Jacob JJ; Mathew K; Thomas N
Endocr Pract; 2007; 13(2):182-6. PubMed ID: 17490934
[TBL] [Abstract][Full Text] [Related]
45. Visual vignette.
Bhadada SK; Das S; Bhansali A; Sen R; Bhattachrya A
Endocr Pract; 2009; 15(6):655. PubMed ID: 19546048
[No Abstract] [Full Text] [Related]
46. Which water for alendronate administration?
Pellegrini R
Osteoporos Int; 2009 Aug; 20(8):1451. PubMed ID: 18958383
[No Abstract] [Full Text] [Related]
47. Uncommon cause for chest pain.
Singh PT; Burad D; Hephzibah J; Paul TV
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29507027
[No Abstract] [Full Text] [Related]
48. Intravenous Bisphosphonate Therapy as a Rescue Analgesic in Refractory Fibrous Dysplasia.
Hatcher L; Henry N; Hooten WM; D'Souza RS
Pain Med; 2022 Dec; 23(12):2085-2089. PubMed ID: 35652736
[No Abstract] [Full Text] [Related]
49. Identifying multiple reports from the same study.
Lin T; Yan SG; Wang C; Cai XZ
Orthopedics; 2011 Nov; 34(11):837-8; author reply 838. PubMed ID: 22050247
[No Abstract] [Full Text] [Related]
50. Letter to the editor: authors' response.
Pradeep AR; Kumari M; Rao NS; Naik SB
J Periodontol; 2014 Nov; 85(11):1479. PubMed ID: 25269526
[No Abstract] [Full Text] [Related]
51. Long-term efficacy of oral alendronate therapy in an elderly patient with polyostotic fibrous dysplasia: A case report.
Li GD; Ogose A; Hotta T; Kawashima H; Ariizumi T; Xu Y; Endo N
Oncol Lett; 2011 Nov; 2(6):1239-1242. PubMed ID: 22848294
[TBL] [Abstract][Full Text] [Related]
52. The Large Pharmaceutical Company Perspective.
Rosenblatt M
N Engl J Med; 2017 Jan; 376(1):52-60. PubMed ID: 28052221
[No Abstract] [Full Text] [Related]
53. Oral alendronate treatment for polyostotic fibrous dysplasia: a case report.
Kitagawa Y; Tamai K; Ito H
J Orthop Sci; 2004; 9(5):521-5. PubMed ID: 15449129
[TBL] [Abstract][Full Text] [Related]
54. Alendronate therapy in polyostotic fibrous dysplasia presenting with pathologic fracture.
Jayaraman M; Karikumar K; Verma A; Modi KD
Am J Orthop (Belle Mead NJ); 2011 Mar; 40(3):E48-50. PubMed ID: 21720608
[TBL] [Abstract][Full Text] [Related]
55. Bisphosphonate therapy for fibrous dysplasia.
DiMeglio LA
Pediatr Endocrinol Rev; 2007 Aug; 4 Suppl 4():440-5. PubMed ID: 17982393
[TBL] [Abstract][Full Text] [Related]
56. Bisphosphonate treatment in polyostotic fibrous dysplasia of the cranium: case report and literature review.
Mansoori LS; Catel CP; Rothman MS
Endocr Pract; 2010; 16(5):851-4. PubMed ID: 20570808
[TBL] [Abstract][Full Text] [Related]
57. Bisphosphonate therapy in polyostotic fibrous dysplasia.
Kumar S
Indian Pediatr; 2004 Oct; 41(10):1069-70. PubMed ID: 15523142
[No Abstract] [Full Text] [Related]
58. Oral bisphosphonates in polyostotic fibrous dysplasia.
Khadilkar VV; Khadilkar AV; Maskati GB
Indian Pediatr; 2003 Sep; 40(9):894-6. PubMed ID: 14530553
[TBL] [Abstract][Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
